Diabetes mellitus increases the risk of different cardiovascular outcomes such as atrial fibrillation, coronary artery disease, heart failure, and cardiovascular deaths [17-18] and thus, clinical trials show the robust cardiovascular benefits of SGLT2 inhibitors for patients with diabetes mellitus, revolutionized clinical practice [1]. This evidence concerns the gene SLC5A2 and diabetes mellitus.